Listed by the USPTO as CHERNYSHEV, OLGA N
Tech Center 3700 • Art Units: 1600 1644 1649 1674 1675 3783
This examiner grants 54% of resolved cases
CHERNYSHEV, OLGA N works in tech center 3700 and art unit 1600, with 963 resolved cases. The allowance rate is 54.5%, and the median time to allowance is 1087 days. The interview lift is 34.0%, making interview engagement a meaningful consideration in a record that otherwise shows a moderate allowance rate.
The leading companies are Abbott Laboratories, The Johns Hopkins University, and Board of Regents of the University of Texas System. The leading firms are SUGHRUE MION, PLLC, CASIMIR JONES, S.C, and Clark+Elbing LLP. Applicants should use interviews alongside disciplined amendment strategy and timeline management.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18147360 | METHODS OF DIAGNOSING BRAIN INJURY | Non-Final OA | Abbott Laboratories |
| 17747397 | METHODS OF EVALUATING BRAIN INJURY IN A PEDIATRIC SUBJECT | Final Rejection | Abbott Laboratories |
| 18657340 | CITRULLINATED BRAIN AND NEUROLOGICAL PROTEINS AS BIOMARKERS OF BRAIN INJURY OR NEURODEGENERATION | Non-Final OA | THE JOHNS HOPKINS UNIVERSITY |
| 16489506 | A NOVEL NERVOUS SYSTEM-SPECIFIC TRANSMEMBRANE PROTEASOME COMPLEX THAT MODULATES NEURONAL SIGNALING THROUGH EXTRACELLULAR SIGNALING VIA BRAIN ACTIVITY PEPTIDES | Non-Final OA | THE JOHNS HOPKINS UNIVERSITY |
| 18707478 | METHODS FOR DEFINING STAGES AND PROGRESSION OF AMYOTROPHIC LATERAL SCLEROSIS | Non-Final OA | The General Hospital Corporation |
| 17914121 | COMPOSITIONS AND METHODS FOR TREATING A NEURODEGENERATIVE OR DEVELOPMENTAL DISORDER | Final Rejection | The Regents of the University of California |
| 17476078 | Use of LEPR Agonists for Pain | Final Rejection | Regeneron Pharmaceuticals, Inc. |
| 18579800 | A Beta Biomarker of Alzheimer’s Disease Model Mouse and Analysis Method Thereof | Non-Final OA | The University of Tokyo |
| 17996498 | PROTEIN MARKERS FOR ASSESSING ALZHEIMER'S DISEASE | Non-Final OA | The Hong Kong University of Science and Technology |
| 18685037 | MYOPEPTIDES AND METHODS OF USE IN TREATING HEART FAILURE | Non-Final OA | Amgen Inc. |
| 17980435 | BLOOD-BASED SCREEN FOR DETECTING NEUROLOGICAL DISEASES IN PRIMARY CARE SETTINGS | Final Rejection | Board of Regents, The University of Texas System |
| 18409571 | PATCHED-1 MONOCLONAL ANTIBODIES AND METHODS OF USE | Non-Final OA | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM |
| 18028932 | PEPTIDE FOR PREVENTING OR TREATING NEURODEGENERATIVE DISEASES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Non-Final OA | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION |
| 17769165 | MUSCLE REGENERATION AND GROWTH | Final Rejection | Brown University |
| 16794379 | METHOD FOR INDEXING COGNITIVE FUNCTION | Final Rejection | SHIMADZU CORPORATION |
| 18293199 | PHARMACEUTICAL COMPOSITION FOR TREATING PERIPHERAL NERVE INJURY | Non-Final OA | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY |
| 16484953 | Methods and Compositions for Treating Neurodegeneration and Fibrosis | Final Rejection | Temple University-Of The Commonwealth System of Higher Education |
| 18511241 | TREATMENT OF MEDICATION OVERUSE HEADACHE USING ANTI-CGRP OR ANTI-CGRP-R ANTIBODIES | Final Rejection | H. Lundbeck A/S |
| 17826334 | METHOD FOR ASSISTING DIAGNOSIS OF PARKINSON'S DISEASE, BIOMARKER, REAGENT KIT, AND DEVICE | Final Rejection | FUJIFILM Wako Pure Chemical Corporation |
| 18002332 | METHOD FOR DETERMINING DISEASE CAUSED BY SYNAPTIC DYSFUNCTION OR DISEASE ACCOMPANIED BY SYNAPTIC DYSFUNCTION | Non-Final OA | AlzMed, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy54.5% of resolved applications examined by Olga N Chernyshev were allowed (963 resolved cases), compared with 37.3% across Art Unit 1600 over the last five years.
This examiner's interview lift is +34.0 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Olga N Chernyshev took 1,087 days on average from filing to allowance.
Olga N Chernyshev examines applications in Art Unit 1600 in Tech Center 3700 (Medical Devices & Mechanical Engineering).
